Investor Presentaiton

Investor presentation Full year 2018 Slide 60 Sustained leadership position in the European modern and new-generation insulin market European insulin market by segment Device penetration - CAGR volume¹: 3.6% European modern insulin and new-generation insulin volume market shares Sanofi Novo Nordisk Eli Lilly tMU 180 160 140 120 100 80 60 40 20 0 Nov 2013 CAGR value¹: 1 CAGR for 5-year period 2 MI: Modern insulin; NGI: New-generation insulin Source: IQVIA monthly MAT Nov, 2018 volume and value figures changing diabetes® MI and NGI penetration Penetration 4.4% 100% 60% 50% 80% Fast-acting 40% 60% 30% Premix 40% 20% Long-acting 20% 10% 0% 0% Nov 2018 Nov 2013 43% 36% 20% Nov 2018 Source: IQVIA monthly MAT Nov, 2018 volume figures, numbers do not add up to 100% due to smaller insulin manufacturers novo nordisk

View entire presentation